PCVX
Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$63.68
+0.09%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -64.3%
- EPS
- -81.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +72.6%
- EPS
- +34.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -65.5%
- EBIT
- -62.2%
- Net income
- -65.2%
- EPS
- -48.2%
- Free cash flow
- -40.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026